GlobeNewswire Inc | Jan 4, 2021 08:30AM EST

January 04, 2021

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Companys website at www.bellerophon.com.

About BellerophonBellerophon Therapeuticsis a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulseprogram, a proprietary pulsatile nitric oxide delivery system. For more information, please visitwww.bellerophon.com.

Contacts At W2O Group: At LifeSci Advisors:Julie Normart Brian Ritchie(559) 974-3245 (212) 915-2578jnormart@w2ogroup.com britchie@lifesciadvisors.com